Current opinion in gastroenterology · 2026
The use of potassium-competitive acid blockers in the management of foregut disease.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghai Megan B, Sloan Joshua A
Аннотация
PURPOSE OF REVIEW: The purpose of this review is to explore the current clinical evidence evaluating the use of potassium-competitive acid blockers (PCABs) in the management of foregut diseases.
RECENT FINDINGS: PCABs have been shown to have clinical superiority over proton pump inhibitors in the management of H. pylori and Los Angeles grade C/D erosive esophagitis. PCABs also are approved for use in nonerosive reflux disease, and data suggest a possible use in peptic ulcer disease.
SUMMARY: There is utility of PCABs in the management of multiple foregut diseases. More data are required to understand the utility of PCABs in the management of Barett's esophagus and eosinophilic esophagitis.
RECENT FINDINGS: PCABs have been shown to have clinical superiority over proton pump inhibitors in the management of H. pylori and Los Angeles grade C/D erosive esophagitis. PCABs also are approved for use in nonerosive reflux disease, and data suggest a possible use in peptic ulcer disease.
SUMMARY: There is utility of PCABs in the management of multiple foregut diseases. More data are required to understand the utility of PCABs in the management of Barett's esophagus and eosinophilic esophagitis.